-
2024-513869-39-00
5
2025-06-27
Obstructive Cardiomyopathy, Hypertrophic
-
2024-515796-35-00
4
2025-06-26
Heart Failure with Preserved Ejection Fraction and Left Ventricular Hy
-
2024-515797-27-00
4
2025-06-25
Heart Failure with Reduced/Mildly Reducede Ejection Fraction and Left
-
2024-512696-12-00
4
2025-06-24
BCR-ABL1+ Chronic Myeloid Leukemia
-
2024-519219-32-00
5
2025-06-23
Heart Failure With Reduced Ejection Fraction
-
2023-507260-40-00
7
2025-06-16
Hemophilia B
-
2023-510294-34-00
5
2025-06-12
small lymphocytic lymphoma (SLL)
-
2024-511534-12-00
7
2025-06-10
Advanced or Metastatic Solid Tumours
-
2024-513122-27-00
5
2025-06-10
Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or
-
2024-513375-40-00
4
2025-05-16
Melanoma
-
2023-506260-14-00
4
2025-05-13
multiple myeloma
-
2024-515053-21-00
4
2025-04-30
Plasma cell leukaemia
-
2024-516030-35-00
5
2025-04-30
Multiple myeloma
-
2024-511495-32-00
5
2025-04-16
Chronic Phase Chronic Myeloid Leukemia
-
2023-509431-29-00
4
2025-04-08
Dilated cardiomyopathy
-
2023-504904-26-00
5
2025-04-07
Progressive Pulmonary Fibrosis
-
2024-515445-42-00
5
2025-03-24
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
-
2024-515511-21-00
4
2025-03-13
Neuroendocrine Carcinoma / G3 Neuroendocrine Tumours
-
2024-512901-22-00
5
2025-02-10
Acute Heart Failure
-
2023-509146-35-00
6
2025-01-30
Systemic Lupus Erythematosus
-
2024-512900-20-00
7
2025-01-30
Non-muscle invasive bladder cancer (NMIBC)
-
2024-513803-15-00
6
2025-01-30
Acute myocarditis
-
2024-519825-39-00
4
2025-01-30
Locally advanced colon cancer (LACC)
-
2024-511188-26-00
5
2024-12-20
Relapsed/refractory multiple myeloma in patients who have received 1 t